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Crimean-Congo hemorrhagic fever virus (C-CHFV) strains
were isolated from a fatal case and the attending physician in
Kosovo, Yugoslavia. Early, rapid diagnosis of the disease was
achieved by reverse transcription-polymerase chain reaction.
The physician was successfully treated with oral ribavirin.
These cases yielded the first genetically studied C-CHFV
human isolates in the Balkans.
 
rimean-Congo hemorrhagic fever (C-CHF) is a tickborne
hemorrhagic fever with documented person-to-person
transmission and a case-fatality rate of approximately 30%.
Nosocomial outbreaks caused by Crimean-Congo hemor-
rhagic fever virus (formal abbreviation, C-CHFV; genus
Nairovirus, family Bunyaviridae) have been reported in sev-
eral countries. This widespread virus has been found in Africa,
Asia, the Middle East, and eastern Europe. C-CHFV was first
identified in the Balkans in 1954. In 1973, Gligic et al. isolated
three C-CHFV strains (Ciflik 1, 6, and 11) from two
Hyalomma  plumbeum plumbeum and one castor bean tick
(Ixodes ricinus) (1). Since then, C-CHF has occurred every
year in the Balkan Peninsula, with the number of cases related
to the number of ticks infected. During the spring and summer
of 2001, an outbreak of C-CHF occurred in Kosovo, with 69
suspected cases, 18 of them laboratory or clinically confirmed,
6 of them fatal (2).
Case Reports
On June 30, 2001, a 43-year-old woman (the patient with
the index case), living in Kosovska Mitrovica, Kosovo,
became severely ill and was admitted to the hospital with high
fever, headache, nausea, generalized myalgia, and disorienta-
tion. Two days later her condition rapidly deteriorated; bleed-
ing from the gastrointestinal tract, she was transferred to the
Institute for Tropical and Infectious Diseases in Belgrade,
where she died a few hours after admission. 
Blood cultures were negative for bacterial pathogens. C-
CHF and hemorrhagic fever with renal syndrome (HFRS)
were suspected, considering the clinical picture of the patient
and the epidemiology of the diseases in this geographic area.
A serum sample collected before death was tested for immu-
noglobulin (Ig) G and IgM specific for a variety of microor-
ganisms (including hantaviruses, rickettsiae, and leptospira)
by enzyme-linked immunosorbent assay and indirect immun-
ofluorescent assay (IFA). No specific antibodies were
detected. 
To detect C-CHFV antibodies, the patient’s serum was
tested in twofold dilutions (initial dilution 1:8) with fluores-
cein-labeled goat anti-human immunoglobulin (Gibco-BRL
Diagnostics, Madison, WI) on spot slides containing Vero E6
cells (ATCC CRL 1586), with approximately 50% of the cells
infected with the prototype Nigerian C-CHFV strain (IbAr
10200). Titers were recorded as the greatest dilution of serum
at which characteristic cytoplasmic immunofluorescence is
detected. No specific antibodies were detected.
On July 6, the 38-year-old physician who had intubated the
index patient when she was admitted became severely ill, with
high fever, asthenia, petechiae, exanthema of soft palate, pneu-
monia symptoms, leukopenia, and thrombocytopenia (leuko-
cyte count: 3x109/L; erythrocyte count: 80x109/L). No
evidence of disseminated intravascular coagulation was
observed.
To detect antigen in the secondary patient’s serum, the
immunoprecipitation procedure was used. Patient’s serum
sample and sera from known C-CHF–positive patients, as well
as hyperimmune human gamma globulin against C-CHFV,
were placed in the wells in agar plates and left overnight to dif-
fuse; precipitin lines were formed where the concentration of
the antigen and antibodies was serologically equivalent (3).
We extracted viral RNA from serum and whole blood sam-
ples from both patients. Complementary DNA was amplified
by nested polymerase chain reaction (PCR) by using primers
from the small (S) RNA segment of C-CHFV (4). We found a
specific 260-bp band in both cases. Nucleotide sequence anal-
ysis was performed by using the OpenGene automated DNA
sequencing system (Visible Genetics Inc., Toronto, Canada).
As expected, the two sequences were identical. We compared
the resulting sequences with those available in the GenBank
database using the BLAST tool (available from: URL: http://
www.ncbi.nlm.nih.gov/BLAST/). We observed a similarity to
C-CHFV S segment sequences. 
Since strong evidence exists that ribavirin is effective for
treating C-CHF (5,6), oral ribavirin was given to the second
patient (800 mg three times on day 1, followed by 600 mg
three times a day for the next 11 days). He responded success-
fully and, after 48 hours, became afebrile; his hematologic and
biochemical parameters returned to normal. No side effects of
ribavirin were present. On July 10, low titers (1:64) of IgM
antibodies were detected, while on July 16, high titers
(1:2,048) of IgG antibodies were detected in patient’s serum
samples. 
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The patient was placed in isolation, and all personnel wore
protective clothing, such as gowns, masks, and gloves.  All
contact persons in the hospital were informed and advised to
contact a physician if any symptoms occurred. No additional
persons became ill. Samples taken from the driver and the
nurse who transferred the woman from the local hospital to
Belgrade were tested by IFA for the presence of antibodies to
C-CHFV and were found negative, even a month after the
woman’s death. 
Whole blood of both C-CHF cases (10% suspension in
phosphate-buffered saline) was injected separately into 25-mL
flasks containing Vero E6 cells. The cells were checked for C-
CHFV antigen by immunofluorescence assay with hyperim-
mune human globulin against C-CHFV (strain Hodja). Posi-
tive cells were detected in both flasks on the 6th day after
injection. The supernatant of the cells was used to infect fresh
E6 cultures, and the virus was passaged six further times. We
designated the virus from the fatal C-CHF case as C-CHFV/
Kosovo/9553/2001, and the virus from the infected physician
as C-CHFV/Kosovo/9717/2001. 
Extraction of viral RNA of cell culture supernatants,
amplification, and phylogenetic analysis showed that the
obtained sequences were identical to each other and to the
sequences amplified from the clinical samples. The nucleotide
sequences were submitted to GenBank and assigned accession
numbers AF428144 (for the index case) and AF428145 (for
the secondary case). Phylogenetic analysis showed that these
sequences clustered together with Drosdov strain (a C-CHFV
strain isolated from blood of a patient in Russia), differing
from it by 4%, while the genetic difference from the prototype
C-CHFV Nigerian strain IbAr 10200 was 17% (Figure). 
Discussion
Because of the severity of C-CHF, this illness has been dif-
ficult to study, either for diagnostic or therapeutic improve-
ments. Antibodies to the virus are not present until 5 days after
onset of illness. In addition, patients who have died of C-CHF
do not usually develop a measurable antibody response. In
these patients, diagnosis is achieved either by isolation of the
virus from blood or tissue samples taken in the first days of ill-
ness or by molecular methods. In our first patient, who died,
no antibodies were detected. Similarly, no antibodies were
present during the first days of illness in the secondary case.
Immunoprecipitation used for antigen detection gave the first
evidence for C-CHF infection in the secondary case.  How-
ever, reverse transcription (RT)-PCR established the diagnosis
of the disease in both cases; sequencing the PCR amplicons
confirmed the result. To our knowledge, this secondary case  is
the first in which PCR was used for rapid diagnosis, although
use of PCR on stored acute-phase samples of infected patients
has been described (4,8). 
In addition, phylogenetic analysis was informative in com-
paring the virus strains at the genetic level, giving insights into
the molecular epidemiology of the disease. The Greek C-
CHFV strain (AP92), not yet associated with disease in
humans, differs greatly from the Kosovo strains (24.3% nucle-
otide difference), forming an independent phylogenetic clade.
Isolation of the virus, the standard for diagnosis, was achieved
in both cases.
The first evidence of the in vitro activity of ribavirin
against C-CHFV and its prophylactic use in patients’ contacts
occurred in 1989 (9), and the effect of oral ribavirin on out-
come in C-CHF patients was described in 1995 (6). Fisher-
Hoch et al. stated that, because of the low frequency of this
disease and its occurrence in rural, often remote, populations,
a formal drug trial is unlikely.  They suggested that the only
likely way to gather sufficient information on therapy was
through an accumulation of reports on similar clusters as they
occur (6). Ribavarin is certainly more effective in intravenous
form, rather than oral; however, intravenous ribavarin is diffi-
cult to obtain. For this reason, in treating the secondary case,
we used its oral form. Recovery was observed a short time
after initiation of treatment, without any side effects of
ribavirin. 
Although the risk for fatal outcome of the secondary case
was not as high, based on criteria described by Swanepoel et
al. (10), we concluded that ribavirin was effective in the
Figure. Phylogenetic relationships based on 255-nt fragment from the
small RNA segment between sequences obtained from this study and
respective representative Crimean-Congo hemorrhagic fever strains
from GenBank. In the phylogenetic tree, sequences of other two
nairoviruses, Dugbe and Hazara, were included; Hazara virus was used
as outgroup. The numbers indicate percentage bootstrap replicates (of
100) calculated by using SEQBOOT, DNADIST, FITCH, and CON-
SENSE from the PHYLIP package (7); values <70% are not shown.
Horizontal distances are proportional to the nucleotide differences. The
scale bar indicates 10% nucleotide sequence divergence. Vertical dis-
tances are for clarity only.DISPATCHES
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patient, as he recovered rapidly after initiation of the treatment
and had a successful immune response.
Concerning the origin of infection of the primary case, no
details are available, such as a tick bite or any contact with C-
CHF cases in the rest of Kosovo, where a C-CHF outbreak
was taking place. No other C-CHF case had been reported
from this region. The first patient died a few hours after admit-
tance to the hospital, and the number of contact persons was
limited. No one had any symptoms or C-CHF antibodies,
except the physician who performed the intubation. He proba-
bly came in contact with patient’s excreta, despite protective
measures.
No tertiary case was detected, as in C-CHF nosocomial
outbreaks in other countries (Pakistan, Dubai, and South
Africa) (6,11–13). The virulence of the virus is likely dimin-
ished on passage, and infectivity from secondary cases is
unusual (12).
Further studies are needed both in diagnostic and treatment
fields to elucidate this life-threatening disease. In addition,
studies at the molecular level might relate the genetic variation
with the pathogenicity of the strains, rendering feasible the
production of an effective vaccine.
Dr. Papa is senior scientist at the Department of Microbiology of
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